MDT

87.14

+2.09%↑

117.12

+2.9%↑

VEEV

172.23

-0.45%↓

HQY

81.97

-0.71%↓

TLRY

6.78

+5.28%↑

MDT

87.14

+2.09%↑

117.12

+2.9%↑

VEEV

172.23

-0.45%↓

HQY

81.97

-0.71%↓

TLRY

6.78

+5.28%↑

MDT

87.14

+2.09%↑

117.12

+2.9%↑

VEEV

172.23

-0.45%↓

HQY

81.97

-0.71%↓

TLRY

6.78

+5.28%↑

MDT

87.14

+2.09%↑

117.12

+2.9%↑

VEEV

172.23

-0.45%↓

HQY

81.97

-0.71%↓

TLRY

6.78

+5.28%↑

MDT

87.14

+2.09%↑

117.12

+2.9%↑

VEEV

172.23

-0.45%↓

HQY

81.97

-0.71%↓

TLRY

6.78

+5.28%↑

Home・Akcijų sąrašas・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

24.58 1.61

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23.52

Max

24.59

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-7.3M -68M
Pardavimai	23M 68M
Pelno marža	-99.318
Darbuotojai	298
EBITDA	42M -15M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+62.87% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	413M 2.1B
Ankstesnė atidarymo kaina	22.97
Ankstesnė uždarymo kaina	24.58

Naujienos nuotaikos

By Acuity

50%

151 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

9.91 / 14.15 Palaikymas ir pasipriešinimas

Syndax Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-07 17:26; UTC

Svarbiausios naujienos

EIA Raises Oil-Price Forecasts as War in Middle East Continues

2026-04-07 23:55; UTC

Rinkos pokalbiai

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

2026-04-07 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Market Talk Roundup: Latest on U.S. Politics

2026-04-07 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

2026-04-07 23:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

2026-04-07 23:42; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-07 23:42; UTC

Rinkos pokalbiai

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

2026-04-07 23:37; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

2026-04-07 23:15; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

2026-04-07 23:04; UTC

Svarbiausios naujienos

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

2026-04-07 23:04; UTC

Svarbiausios naujienos

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

2026-04-07 23:03; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-07 23:03; UTC

Rinkos pokalbiai

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

2026-04-07 23:01; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

2026-04-07 22:58; UTC

Svarbiausios naujienos

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

2026-04-07 21:56; UTC

Įsigijimai, susijungimai, perėmimai

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

2026-04-07 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-07 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-07 19:45; UTC

Rinkos pokalbiai

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

2026-04-07 19:17; UTC

Svarbiausios naujienos

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

2026-04-07 19:16; UTC

Rinkos pokalbiai

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

2026-04-07 19:07; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-07 19:07; UTC

Rinkos pokalbiai

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

2026-04-07 18:41; UTC

Įsigijimai, susijungimai, perėmimai

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

2026-04-07 18:40; UTC

Įsigijimai, susijungimai, perėmimai

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

2026-04-07 18:39; UTC

Įsigijimai, susijungimai, perėmimai

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

2026-04-07 18:24; UTC

Svarbiausios naujienos

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026-04-07 17:08; UTC

Rinkos pokalbiai

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

2026-04-07 16:21; UTC

Svarbiausios naujienos

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026-04-07 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Syndax Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

62.87% į viršų

12 mėnesių prognozė

Vidutinis 39.56 USD 62.87%

Aukščiausias 57 USD

Žemiausias 28 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Syndax Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

Pirkti

Laikyti

Parduoti

Remiantis 10 analitikų, pateikusių Syndax Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

9.91 / 14.15Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Rinkos nuotaikos

By Acuity

151 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.